These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30325912)

  • 21. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
    Zhang L; Qu X; Teng Y; Shi J; Yu P; Sun T; Wang J; Zhu Z; Zhang X; Zhao M; Liu J; Jin B; Luo Y; Teng Z; Dong Y; Wen F; An Y; Yuan C; Chen T; Zhou L; Chen Y; Zhang J; Wang Z; Qu J; Jin F; Zhang J; Jin X; Xie X; Wang J; Man L; Fu L; Liu Y
    J Clin Oncol; 2017 Nov; 35(31):3558-3565. PubMed ID: 28854065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].
    Nomura H; Kawakami H; Nagai S; Shinohara T; Imoto S; Isaka H
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):941-6. PubMed ID: 18633221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impairment of liver synthetic function and the production of plasma proteins in primary breast cancer patients on doxorubicincyclophosphamide (AC) protocol.
    Saleem Z; Ahmad M; Hashmi FK; Saeed H; Aziz MT
    Pak J Pharm Sci; 2016 Sep; 29(5):1555-1563. PubMed ID: 27731812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin and cyclophosphamide-induced parotitis: A case report.
    Fox-Lewis A; Tairab M; Fulton G; Kuper-Hommel M; Jameson MB
    J Clin Pharm Ther; 2020 Feb; 45(1):211-213. PubMed ID: 31539173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients. a prospective, comparative, non-randomised study.
    Fiets WE; van Helvoirt RP; Nortier JW; van der Tweel I; Struikmans H
    Eur J Cancer; 2003 May; 39(8):1081-8. PubMed ID: 12736107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study in a variety of practice settings in Kyushu].
    Anan K; Mitsuyama S; Taniguchi H; Yamamoto Y; Fujiyoshi K; Tateishi T; Tamura K
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1417-22. PubMed ID: 17033230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
    Legha SS; Ajani JA; Blumenschein GR; Hortobagyi GN; Buzdar AU
    Cancer; 1984 May; 53(9):1836-40. PubMed ID: 6231092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].
    Baba S; Kashimura M; Shinohara M; Kusano S; Sasayama T; Hamasaki K
    Gan No Rinsho; 1989 Feb; 35(3):371-7. PubMed ID: 2926985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of metoclopramide and dexamethasone in preventing vomiting associated with antineoplastic chemotherapy].
    Sobkowski W; Jassem J
    Pol Tyg Lek; 1987 Jul 6-7; 42(27-28):841-3. PubMed ID: 3684761
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
    Morita M; Kishi S; Ookura M; Matsuda Y; Tai K; Yamauchi T; Ueda T
    Curr Probl Cancer; 2017; 41(6):419-425. PubMed ID: 29061362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
    Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast.
    Palappallil DS; Nair BL; Jayakumar KL; Puvathalil RT
    Indian J Cancer; 2011; 48(1):68-73. PubMed ID: 21248442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
    Hecht JR; Lembo T; Chap L
    Cancer; 1997 May; 79(9):1698-702. PubMed ID: 9128984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.